Japan’s Order-Made To Begin Testing First Product
This article was originally published in PharmAsia News
Executive Summary
Order-Made Souyaku, a Japanese start-up biotech, plans to begin trials this spring in the United Kingdom for its first candidate, a drug to treat irritable-bowel syndrome. Order-Made's first drug, OMS210, is designed to bond with serotonin receptors to reduce overactivity of the bowel without the side effects associated with existing drugs. The start-up licensed the rights to the drug from R&R, a U.S. biotech venture, to develop it in China, the European Union, Japan, South Korea and the U.S. (Click here for more - a subscription may be required